IGI Logo

Below are Views On Strides up by 2.5% on positive development of receiving approval from USFDA By Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

“Strides Pharma Science Limited (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Prednisone Tablets USP, 10 mg and 20 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Deltasone Tablets, 10 mg and 20 mg, of Pharmacia and Upjohn Co. (Pharmacia). According to IQVIA MAT December 2020 data, the US market for Prednisone Tablets USP, 10 mg and 20 mg is approximately US$ 60 Mn. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.   This will be a small product for strides and will not create a major impact on its financials and valuations.”

Above views are of the author and not of the website kindly read disclaimer